Abstract:Objectives and design:Developing an effective HIV-1 vaccine that elicits broadly neutralizing HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have revealed various strategies employed by the virus to escape host immune surveillance. Here, we investigated the human antibody gene repertoires of uninfected and HIV-1-infected individuals at genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput sequence analysis to determine the frequencies of putative germline antibody genes of known HIV-1 monoclonal bnAbs (bnmAbs).Methods:Combinatorial gDNA and cDNA antibody libraries were constructed using the gDNAs and mRNAs isolated from uninfected and HIV-1-infected human peripheral blood mononuclear cells (PBMCs). All libraries were deep sequenced and sequences analysed using IMGT/HighV-QUEST software (http://imgt.org/HighV-QUEST/index.action). The frequencies of putative germline antibodies of known bnmAbs in the gDNA and cDNA libraries were determined.Results and conclusion:The human gDNA antibody libraries were more diverse in heavy and light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely low in human antibody gene repertoires. However, we found relatively high frequencies of the heavy and kappa and lambda light chain variable regions that used the same V-genes and had the same CDR3 lengths as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such heavy and kappa and lambda light chain variable regions may be stimulated to induce HIV-1 bnAbs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

Immune Perturbations in HIV-1–infected Individuals Who Make Broadly Neutralizing Antibodies

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

The XbnAb Cohort: 304 people with broadly neutralizing antibody activity to HIV-1

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Neutralization activity in chronic HIV infection is characterized by a distinct programming of follicular helper CD4 T cells

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Autoreactivity and Broad Neutralization of Antibodies Against HIV-1 Are Governed by Distinct Mutations: Implications for Vaccine Design Strategies

Development of Neutralization Breadth against Diverse HIV‐1 by Increasing Ab–Ag Interface on V2

Host controls of HIV broadly neutralizing antibody development

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Augmenting Neutralization Breadth Against Diverse HIV-1 by Increasing the Ab-Ag Interface on V2

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1

Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

Vaccination Induces Maturation of Diverse Unmutated VRC01-class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model

Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site

Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction